Does high SHBG plus reduced androgen production lower free testosterone?

In postmenopausal women, the intersection of declining ovarian androgen production and alterations in binding proteins creates a profound state of functional androgen depletion.

Mechanistic synergy of SHBG and androgen decline

• Circulating testosterone dynamics are governed by a strict mass-action equilibrium (modeled by the Vermeulen and Södergård equations) where free testosterone normally constitutes only 1% to 3% of the total pool.
• When absolute ovarian androgen production declines, the baseline pool available to enter the free compartment is restricted.
• This restriction is compounded by sex hormone-binding globulin (SHBG), which binds testosterone with high affinity (association constant $K_a \approx 10^9$ L/mol).
• As SHBG levels rise relative to a diminished total testosterone pool, SHBG disproportionately sequesters the remaining hormone, shifting the equilibrium to the protein-bound compartment and causing a non-linear, compounded reduction in absolute free (bioavailable) testosterone.

Clinical implications and therapeutic influences

• Exogenous factors such as oral estrogen therapy actively stimulate hepatic synthesis of SHBG, further compounding the depletion of the free testosterone pool.
• Clinically, this reduction in bioavailable androgens has protective oncological implications; lower circulating concentrations of free testosterone are associated with a reduced risk of breast and endometrial cancers in postmenopausal women.
• Because of these non-linear dynamics, evaluating total testosterone alone is insufficient to assess functional androgen status in postmenopausal clinical presentations.

Bottom line

• Reduced androgen production and elevated SHBG synergistically deplete bioavailable testosterone, as a smaller absolute hormone pool is met with highly efficient protein binding—a state that is exacerbated by oral estrogens but offers a protective effect against breast and endometrial cancers.